{"entity":{"id":"nct07797907","kind":"trial","name":"This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer.","aka":[],"tldr":"A phase 1 trial of BD200 run by Biolojic Design Ltd., not yet recruiting.","summary":"This Clinical Study is to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Antitumor Activity of BD200 in Participants With Advanced or Metastatic Cancer. is a phase 1 interventional study registered as NCT07797907 by Biolojic Design Ltd., with 110 participants planned, started 2026-12-31. Conditions recorded: Solid Tumor (Phase I). Interventions recorded: BD200 and BD200.","status":"planned","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT07797907","url":"https://clinicaltrials.gov/study/NCT07797907"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["bd200"],"companies":["biolojic-design"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07797907","phase":"1","setting":"A Phase 1a/b, First-in-Human Dose Escalation and Dose Expansion Clinical Study of the Dual Targeting Trop-2 and Nectin-4 Multibody Drug Conjugate BD200 in Participants With Select Unresectable Locally Advanced or Metastatic Cancers","sponsor":"Biolojic Design Ltd.","enrolled":110,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07797907/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"bd200","kind":"drug","name":"BD200","route":"/drugs/bd200/"}],"company":[{"id":"biolojic-design","kind":"company","name":"Biolojic Design","route":"/companies/biolojic-design/"}]}}